CoChat
Sign Up
Cited by 335Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial

Open access
Craft, Suzanne, Claxton, Amy, Baker, Laura D., Hanson, Angela J., Cholerton, Brenna, Trittschuh, Emily H., Dahl, Deborah, Caulder, Erin, Neth, Bryan, Montine, Thomas J., Jung, Youngkyoo, Maldjian, Joseph, Whitlow, Christopher, Friedman, Seth·2017·Journal of Alzheimer’s Disease
DOI 10.3233/jad-161256PMC PMC5409050
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Long acting insulin detemir administered intranasally for three weeks enhanced memory for adults with Alzheimer’s disease dementia (AD) or amnestic mild cognitive impairment (MCI). The investigation of longer-term administration is necessary to determine whether benefits persist, whether they are similar to benefits provided by regular insulin, and whether either form of insulin therapy affects AD biomarkers. Objective: The present study aimed to determine whether four months of treatment with intranasal insulin detemir or regular insulin improves cognition, daily functioning, and AD biomarkers for adults with MCI or AD. Methods: This randomized, double-blind, placebo-controlled trial included an intent-to-treat sample consisting of 36 adults diagnosed with MCI or mild to moderate AD. Participants received placebo ( n = 12), 40 IU of insulin detemir ( n = 12), or 40 IU of regular insulin ( n = 12) daily for four months, administered with a nasal delivery device. A cognitive battery was administered at baseline and after two and four months of treatment. MRI was administered for all participants and lumbar puncture for a subset ( n = 20) at baseline and four months. The primary outcome was change from baseline to four months on a memory composite (sum of Z scores for delayed list and story recall). Secondary outcomes included: global cognition (Alzheimer’s Disease Assessment Scale-Cognition), daily functioning (Dementia Severity Rating Scale), MRI volume changes in AD-related regions of interest, and cerebrospinal fluid AD markers. Results: The regular insulin treated group had better memory after two and four months compared with placebo ( p < 0.03). No significant effects were observed for the detemir-assigned group compared with the placebo group, or for daily functioning for either group. Regular insulin treatment was associated with preserved volume on MRI. Regular insulin treatment was also associated with reduction in the tau-P181/Aβ 42 ratio. Conclusion: Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-161256

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Enrollment data for study participants.
Fig.1 Enrollment data for study participants.CC BY-NC · PubMed Central
Fig.2 Change from baseline for delayed memory composite Z score for placebo-assigned, regular insulin-treated, and detemir-treated groups. The regular insulin group had improved memory compared with the placebo group after two (p < 0.03) and four (p < 0.05) months of treatment. No differences were observed between placebo and detemir groups.
Fig.2 Change from baseline for delayed memory composite Z score for placebo-assigned, regular insulin-treated, and detemir-treated groups. The regular insulin group had improved memory compared with the placebo group after two (p < 0.03) and four (p < 0.05) months of treatment. No differences were observed between placebo and detemir groups.CC BY-NC · PubMed Central
Fig.3 Change from baseline volume (cm3) for key AD-related ROIs. Increased or preserved volumes were noted in four ROIs for the regular insulin-treated group compared with the placebo group: (A) left superior parietal cortex; (B) right middle cingulum; (C) left cuneus; (D) right parahippocampal gyrus (all ps < 0.05). Decreased volume was observed for the detemir group relative to placebo for (E) right cuneus and (F) right hippocampus (ps < 0.01 and 0.05), whereas preserved volume was observed for (G) left anterior cingulum and (H) left middle cingulum (ps < 0.05).
Fig.3 Change from baseline volume (cm3) for key AD-related ROIs. Increased or preserved volumes were noted in four ROIs for the regular insulin-treated group compared with the placebo group: (A) left superior parietal cortex; (B) right middle cingulum; (C) left cuneus; (D) right parahippocampal gyrus (all ps < 0.05). Decreased volume was observed for the detemir group relative to placebo for (E) right cuneus and (F) right hippocampus (ps < 0.01 and 0.05), whereas preserved volume was observed for (G) left anterior cingulum and (H) left middle cingulum (ps < 0.05).CC BY-NC · PubMed Central
Fig.4 Representative relationships between changes in MRI volume and cognitive outcomes. For regular insulin-treated participants, improved memory composite Z scores were associated with increased volume for (A) right middle cingulum (r = 0.62, p < 0.05), (B) left cuneus (r = 0.82, p < 0.01), (C) left inferior parietal (r = 0.61, p < 0.04) and (D) right superior frontal (r = 0.67, p < 0.03). For the placebo group, participants who had less volume loss in (C) left inferior parietal or (D) right superior frontal cortex showed less memory decline (rs = 0.65 and 0.64, ps < 0.05). No relationships between ROI volumes and memory were observed for the detemir-treated group.
Fig.4 Representative relationships between changes in MRI volume and cognitive outcomes. For regular insulin-treated participants, improved memory composite Z scores were associated with increased volume for (A) right middle cingulum (r = 0.62, p < 0.05), (B) left cuneus (r = 0.82, p < 0.01), (C) left inferior parietal (r = 0.61, p < 0.04) and (D) right superior frontal (r = 0.67, p < 0.03). For the placebo group, participants who had less volume loss in (C) left inferior parietal or (D) right superior frontal cortex showed less memory decline (rs = 0.65 and 0.64, ps < 0.05). No relationships between ROI volumes and memory were observed for the detemir-treated group.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 335

Related

See all

Metadata

Authors
Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., Jung, Y., Maldjian, J., Whitlow, C., & Friedman, S.
Affiliations
  • Wake Forest University Health Sciences (US)
  • Alkermes (United States) (US)
  • University of Washington (US)
  • Stanford Medicine (US)
  • The University of Texas Southwestern Medical Center (US)
  • Seattle Children's Hospital (US)
Corresponding author
Craft, Suzanne
ORCID
Venue
Journal of Alzheimer’s Disease
Publisher
SAGE Publications
Published
2017-03-29
Volume
57
Issue
4
Pages
1325-1334
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
DOI
10.3233/jad-161256
PMC
PMC5409050
OpenAlex
W2600568015
Cited by
335
References
33
Citations by year
2026: 13 · 2025: 40 · 2024: 25 · 2023: 47 · 2022: 32 · 2021: 46 · 2020: 49 · 2019: 46 · 2018: 29 · 2017: 8
FWCI
26.70
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Alzheimer's Association (ZEN-10-173646)
  • National Institute on Aging (P30AG049638)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
intranasal insulin, insulin detemir
MeSH terms
Activities of Daily Living, Aged, Alzheimer Disease, Brain, Cognition, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Organ Size, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Outcome, Nootropic Agents, Insulins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review